Janssen pays $10m upfront to license technology for Nucynta ER from Depomed
This article was originally published in Scrip
Executive Summary
Depomed will earn $10 million upfront and low single-digit royalties through the end of 2021 on sales of Nucynta ER (tapentadol extended-release tablets) in the US, Canada and Japan under an agreement with Janssen Pharmaceuticals for a non-exclusive license and certain other rights to patents for Depomed's Acuform gastric retentive drug delivery technology.